Literature DB >> 17272610

Gabapentin successfully manages chronic unexplained irritability in children with severe neurologic impairment.

Julie M Hauer1, Beverly S Wical, Lawrence Charnas.   

Abstract

Neurologically impaired children have an increased frequency of recurrent pain and irritability that persist in some despite comprehensive evaluation and management of possible pain sources. We hypothesized that visceral hyperalgesia was a source of chronic unexplained irritability and report the outcome of gabapentin treatment in 9 severely neurologically impaired children. Caregivers reported marked improvement after treatment ranging from 3 months to 3 years. Nystagmus in 1 child was the only noted adverse effect. Visceral hyperalgesia may be a source of unexplained irritability in the neurologically impaired child. Symptoms may improve with gabapentin treatment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17272610     DOI: 10.1542/peds.2006-1609

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  19 in total

1.  The Use of Gabapentin for Pain and Agitation in Neonates and Infants in a Neonatal ICU.

Authors:  Gretchen L Sacha; Maria G Foreman; Kay Kyllonen; Ricardo J Rodriguez
Journal:  J Pediatr Pharmacol Ther       Date:  2017 May-Jun

2.  Gabapentin Use for Hospitalized Neonates.

Authors:  Hibo H Abdi; Nathalie L Maitre; Kristen L Benninger; Mark E Hester; Jonathan L Slaughter
Journal:  Pediatr Neurol       Date:  2019-02-21       Impact factor: 3.372

3.  Gabapentin Improves Oral Feeding in Neurologically Intact Infants With Abdominal Disorders.

Authors:  Keliana L O'Mara; Saleem Islam; Janice A Taylor; Daniel Solomon; Michael D Weiss
Journal:  J Pediatr Pharmacol Ther       Date:  2018 Jan-Feb

4.  Physician variability in treating pain and irritability of unknown origin in children with severe neurological impairment.

Authors:  Harold B Siden; Bruce C Carleton; Tim F Oberlander
Journal:  Pain Res Manag       Date:  2013-07-24       Impact factor: 3.037

5.  Low-dose amitriptyline-induced acute dystonia in a patient with metachromatic leukodystrophy.

Authors:  Gerarda Cappuccio; Nicola Brunetti-Pierri; Gaetano Terrone; Alfonso Romano; Generoso Andria; Ennio Del Giudice
Journal:  JIMD Rep       Date:  2012-10-30

Review 6.  Assessment, pharmacological therapy and rehabilitation management of musculoskeletal pain in children with mucopolysaccharidoses: a scoping review.

Authors:  R Gnasso; B Corrado; I Iommazzo; F Migliore; G Magliulo; B Giardulli; C Ruosi
Journal:  Orphanet J Rare Dis       Date:  2022-07-08       Impact factor: 4.303

Review 7.  Challenging neurological symptoms in paediatric palliative care: An approach to symptom evaluation and management in children with neurological impairment.

Authors:  Lisa Ann Rasmussen; Marie-Claude Grégoire
Journal:  Paediatr Child Health       Date:  2015-04       Impact factor: 2.253

8.  Gabapentin Use in the Neonatal Intensive Care Unit.

Authors:  Laura Edwards; Stephen DeMeo; Chi D Hornik; C Michael Cotten; P Brian Smith; Carolyn Pizoli; Julie M Hauer; Margarita Bidegain
Journal:  J Pediatr       Date:  2015-11-11       Impact factor: 4.406

9.  Moving from tube to oral feeding in medically fragile nonverbal toddlers.

Authors:  Ann McGrath Davis; Amanda Schurle Bruce; Cathy Mangiaracina; Trina Schulz; Paul Hyman
Journal:  J Pediatr Gastroenterol Nutr       Date:  2009-08       Impact factor: 2.839

10.  Gabapentin Effects on PKC-ERK1/2 Signaling in the Spinal Cord of Rats with Formalin-Induced Visceral Inflammatory Pain.

Authors:  Yan-Bo Zhang; Zheng-Dong Guo; Mei-Yi Li; Peter Fong; Ji-Guo Zhang; Can-Wen Zhang; Ke-Rui Gong; Ming-Feng Yang; Jing-Zhong Niu; Xun-Ming Ji; Guo-Wei Lv
Journal:  PLoS One       Date:  2015-10-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.